Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo.
Wymann S, Mischnik M, Leong D, Ghosh S, Tan X, Cao H, Kuehnemuth B, Powers GA, Halder P, de Souza MJ, James HS, Tomasetig V, Lind H, Rossato P, Owczarek CM, Ow SY, Dower SK, Baz Morelli A, Rowe T, Hardy MP.
Wymann S, et al. Among authors: lind h.
Biochem J. 2022 May 13;479(9):1007-1030. doi: 10.1042/BCJ20220054.
Biochem J. 2022.
PMID: 35470373